FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2417402543> ?p ?o ?g. }

• W2417402543 endingPage "1162" @default.
• W2417402543 startingPage "1162" @default.
• W2417402543 abstract "<h3>Importance</h3> Oxaliplatin added to fluorouracil plus leucovorin therapy for patients with colon cancer has been shown to provide significant but modest absolute benefit for disease-free survival. However, acute and chronic neurotoxic effects from this regimen underscore the need for markers that predict oxaliplatin benefit. <h3>Objective</h3> To test our hypothesis that molecular subtypes of colon cancer would be associated with differential prognosis and benefit from oxaliplatin added to fluorouracil plus leucovorin therapy. <h3>Design, Setting, and Participants</h3> Participants in the NSABP C-07 trial were divided into discovery (n = 848) and validation (n = 881) cohorts based on the order of tissue block submission. A reestimated centroid using 72 genes was used to determine Colorectal Cancer Assigner subtypes and their association with oxaliplatin benefit in the discovery cohort. The validation cohort was examined with a locked-down algorithm for subtype classification and statistical analysis plan. Post hoc analysis included examination of the entire cohort with Colorectal Cancer Assigner, Colorectal Cancer Subtype (CCS), and Consensus Molecular Subtype (CMS) methods. <h3>Interventions</h3> Fluorouracil plus leucovorin with or without oxaliplatin. <h3>Main Outcomes and Measures</h3> Percent recurrence-free survival. <h3>Results</h3> Among 1729 patients, 744 (43%) were female and mean (SD) age was 58 (11) years. Although C-07 participants with stage III disease with an enterocyte subtype showed a statistically significant benefit from oxaliplatin in the discovery cohort (hazard ratio, 0.22 [95% CI, 0.09-0.56];<i>P</i> = .001 [N = 65]), no statistically significant benefit was observed in the validation cohort (hazard ratio, 0.53 [95% CI, 0.22-1.24];<i>P</i> = .14 [N = 70]). The stemlike subtype was associated with poor prognosis and lack of benefit from oxaliplatin treatment (HR, 0.99 [95% CI, 0.73-1.34];<i>P</i> = .96 [N = 367]). Examination of the different subtyping methods shows that all 3 methods robustly identified patients with poor prognosis (stemlike, CCS-3, and CMS-4) in both stage II and III. <h3>Conclusions and Relevance</h3> Patients with stemlike tumors may be appropriate for clinical trials testing experimental therapies because stemlike tumors were robustly identified and associated with a poor prognosis regardless of stage or chemotherapy regimen. The clinical utility of using subtyping for the identification of patients for treatment with oxaliplatin requires validation in independent clinical trial cohorts. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT00004931" @default.
• W2417402543 created "2016-06-24" @default.
• W2417402543 creator A5009480096 @default.
• W2417402543 creator A5024815774 @default.
• W2417402543 creator A5032074477 @default.
• W2417402543 creator A5033033849 @default.
• W2417402543 creator A5037102607 @default.
• W2417402543 creator A5055013606 @default.
• W2417402543 creator A5057918523 @default.
• W2417402543 creator A5062302578 @default.
• W2417402543 creator A5065332366 @default.
• W2417402543 creator A5069843364 @default.
• W2417402543 creator A5073879846 @default.
• W2417402543 creator A5079315515 @default.
• W2417402543 date "2016-09-01" @default.
• W2417402543 modified "2023-10-15" @default.
• W2417402543 title "Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes" @default.
• W2417402543 cites W1481972425 @default.
• W2417402543 cites W1924058902 @default.
• W2417402543 cites W1934094702 @default.
• W2417402543 cites W2038143310 @default.
• W2417402543 cites W2085963386 @default.
• W2417402543 cites W2108516575 @default.
• W2417402543 cites W2111807726 @default.
• W2417402543 cites W2113499049 @default.
• W2417402543 cites W2118950501 @default.
• W2417402543 cites W2131072420 @default.
• W2417402543 cites W2138550913 @default.
• W2417402543 cites W2138994529 @default.
• W2417402543 cites W2154941270 @default.
• W2417402543 cites W2171232394 @default.
• W2417402543 doi "https://doi.org/10.1001/jamaoncol.2016.2314" @default.
• W2417402543 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5065181" @default.
• W2417402543 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27270348" @default.
• W2417402543 hasPublicationYear "2016" @default.
• W2417402543 type Work @default.
• W2417402543 sameAs 2417402543 @default.
• W2417402543 citedByCount "133" @default.
• W2417402543 countsByYear W24174025432016 @default.
• W2417402543 countsByYear W24174025432017 @default.
• W2417402543 countsByYear W24174025432018 @default.
• W2417402543 countsByYear W24174025432019 @default.
• W2417402543 countsByYear W24174025432020 @default.
• W2417402543 countsByYear W24174025432021 @default.
• W2417402543 countsByYear W24174025432022 @default.
• W2417402543 countsByYear W24174025432023 @default.
• W2417402543 crossrefType "journal-article" @default.
• W2417402543 hasAuthorship W2417402543A5009480096 @default.
• W2417402543 hasAuthorship W2417402543A5024815774 @default.
• W2417402543 hasAuthorship W2417402543A5032074477 @default.
• W2417402543 hasAuthorship W2417402543A5033033849 @default.
• W2417402543 hasAuthorship W2417402543A5037102607 @default.
• W2417402543 hasAuthorship W2417402543A5055013606 @default.
• W2417402543 hasAuthorship W2417402543A5057918523 @default.
• W2417402543 hasAuthorship W2417402543A5062302578 @default.
• W2417402543 hasAuthorship W2417402543A5065332366 @default.
• W2417402543 hasAuthorship W2417402543A5069843364 @default.
• W2417402543 hasAuthorship W2417402543A5073879846 @default.
• W2417402543 hasAuthorship W2417402543A5079315515 @default.
• W2417402543 hasBestOaLocation W24174025431 @default.
• W2417402543 hasConcept C121608353 @default.
• W2417402543 hasConcept C126322002 @default.
• W2417402543 hasConcept C143998085 @default.
• W2417402543 hasConcept C167135981 @default.
• W2417402543 hasConcept C201903717 @default.
• W2417402543 hasConcept C207103383 @default.
• W2417402543 hasConcept C2780456651 @default.
• W2417402543 hasConcept C2780962732 @default.
• W2417402543 hasConcept C2781413609 @default.
• W2417402543 hasConcept C44249647 @default.
• W2417402543 hasConcept C526805850 @default.
• W2417402543 hasConcept C71924100 @default.
• W2417402543 hasConcept C72563966 @default.
• W2417402543 hasConceptScore W2417402543C121608353 @default.
• W2417402543 hasConceptScore W2417402543C126322002 @default.
• W2417402543 hasConceptScore W2417402543C143998085 @default.
• W2417402543 hasConceptScore W2417402543C167135981 @default.
• W2417402543 hasConceptScore W2417402543C201903717 @default.
• W2417402543 hasConceptScore W2417402543C207103383 @default.
• W2417402543 hasConceptScore W2417402543C2780456651 @default.
• W2417402543 hasConceptScore W2417402543C2780962732 @default.
• W2417402543 hasConceptScore W2417402543C2781413609 @default.
• W2417402543 hasConceptScore W2417402543C44249647 @default.
• W2417402543 hasConceptScore W2417402543C526805850 @default.
• W2417402543 hasConceptScore W2417402543C71924100 @default.
• W2417402543 hasConceptScore W2417402543C72563966 @default.
• W2417402543 hasIssue "9" @default.
• W2417402543 hasLocation W24174025431 @default.
• W2417402543 hasLocation W24174025432 @default.
• W2417402543 hasLocation W24174025433 @default.
• W2417402543 hasLocation W24174025434 @default.
• W2417402543 hasOpenAccess W2417402543 @default.
• W2417402543 hasPrimaryLocation W24174025431 @default.
• W2417402543 hasRelatedWork W1968396325 @default.
• W2417402543 hasRelatedWork W2163079911 @default.
• W2417402543 hasRelatedWork W2169729194 @default.
• W2417402543 hasRelatedWork W2348071463 @default.
• W2417402543 hasRelatedWork W2358719358 @default.

• next